Naimisha Movva

Naimisha Movva

Auto-generated profile, based on publicly available information

Naimisha Movva

EpidStrategies, A Division of ToxStrategies, LLC, Mission Viejo, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
XJXiaohui Jiang
Xiaohui Jiang
LBLauren C Bylsma
Lauren C Bylsma
HRHeidi Reichert
Heidi Reichert
CNChristopher B Nelson
Christopher B Nelson
Background: This study describes leading causes of hospitalization, including respiratory syncytial virus (RSV), in United States infants (10% of total infant hospitalizations from December through March, reaching >15% in January–February. From 2009 through 2011, acute bronchiolitis due to RSV was the leading primary diagnosis in every birth month. Acute bronchiolitis due to RSV was the leading cause among all races/ethnicities, except Asian/Pacific Islanders, and all insurance payer groups. KID analyses confirmed these results. Conclusions: Acute bronchiolitis due to RSV is the leading cause of US infant hospitalizations.

15 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
XJXiaohui Jiang
Xiaohui Jiang
HRHeidi Reichert
Heidi Reichert
LBLauren C Bylsma
Lauren C Bylsma
CNChristopher B Nelson
Christopher B Nelson
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations in United States infants aged <1 year, but research has focused on select populations. National (Nationwide) Inpatient Sample and National Emergency Department (ED) Sample data (2011–2019) were used to report RSV hospitalization (RSVH), bronchiolitis hospitalization (BH), and ED visit counts, percentage of total hospitalizations/visits, and rates per 1000 live births along with inpatient mortality, mechanical ventilation (MV), and total charges (2020 US dollars). Average annual RSVH and RSV ED visits were 56 927 (range, 43 845–66 155) and 131 999 (range, 89 809–177 680), respectively. RSVH rates remained constant over time (P = .5), whereas ED visit rates increased (P = .004). From 2011 through 2019, Medicaid infants had the highest average rates (RSVH: 22.3 [95% confidence interval {CI}, 21.5–23.1] per 1000; ED visits: 55.9 [95% CI, 52.4–59.4] per 1000) compared to infants with private or other/unknown insurance (RSVH: P < .0001; ED visits: P < .0001). From 2011 through 2019, for all races and ethnicities, Medicaid infants had higher average RSVH rates (up to 7 times) compared to infants with private or other/unknown insurance. RSVH mortality remained constant over time (P = .8), whereas MV use (2019: 13% of RSVH, P < .0001) and mean charge during hospitalization (2019: $21 513, P < .0001) increased. Bronchiolitis patterns were similar. This study highlights the importance of ensuring access to RSV preventive measures for all infants.

16 April 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
HRHeidi Reichert
Heidi Reichert
MSMina Suh
Mina Suh
XJXiaohui Jiang
Xiaohui Jiang
NMNaimisha Movva
Naimisha Movva
LBLauren C Bylsma
Lauren C Bylsma
CNChristopher B Nelson
Christopher B Nelson
Infant mortality due to respiratory syncytial virus (RSV) in the United States is not well understood. From 1999 to 2018, RSV, bronchiolitis, and influenza deaths were described for infants <1 year using linked birth/death datasets from the National Vital Statistics System. Mortality was described overall and by infant birth and death characteristics. Bronchiolitis was included as the plausible upper limit of RSV, while influenza served as a comparator. Total infant deaths were 561 RSV, 1603 bronchiolitis, and 504 influenza, and rates were 6.9 (95% confidence interval [CI], 6.4–7.5), 19.8 (95% CI, 18.9–20.8), and 6.2 (95% CI, 5.7–6.8) per 1 000 000 live births, respectively. The highest RSV rates were observed among <29 weeks’ gestational age infants (103.5; 95% CI, 81.8–129.1), American Indian/Alaskan Native (20.3; 95% CI, 11.6–33.0), and Medicaid-insured (7.3; 95% CI, 5.9–8.9). However, RSV mortality burden was greatest in full-term (53.7%), white (44.9%), and Medicaid-insured (61.7%) infants. Deaths outside the inpatient setting were 21% and 54% for RSV and bronchiolitis; more Medicaid- (58%) and other/unknown-insured (69%) infants with bronchiolitis died outside of the inpatient setting, compared to privately insured infants (48%) (P = .0327). These national estimates emphasize the importance of considering all infants across all healthcare settings when describing RSV mortality.

15 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
NMNaimisha Movva
Naimisha Movva
MSMina Suh
Mina Suh
HRHeidi Reichert
Heidi Reichert
BHBradley Hintze
Bradley Hintze
MSMark P Sendak
Mark P Sendak
WMWilliam F Malcolm
William F Malcolm
Background: Surveillance in 2020–2021 showed that seasonal respiratory illnesses were below levels seen during prior seasons, with the exception of interseasonal respiratory syncytial virus (RSV). Methods: Electronic health record data of infants aged <1 year visiting the Duke University Health System from 4 October 2015 to 28 March 2020 (pre–COVID-19) and 29 March 2020 to 30 October 2021 (COVID-19) were assessed. International Classification of Diseases-Tenth Revision (ICD-10) codes for RSV (B97.4, J12.1, J20.5, J21.0) and bronchiolitis (RSV codes plus J21.8, J21.9) were used to detail encounters in the inpatient (IP), emergency department (ED), outpatient (OP), urgent care (UC), and telemedicine (TM) settings. Results: Pre–COVID-19, 88% of RSV and 92% of bronchiolitis encounters were seen in ambulatory settings. During COVID-19, 94% and 93%, respectively, occurred in ambulatory settings. Pre–COVID-19, the highest RSV proportion was observed in December–January (up to 38% in ED), while the peaks during COVID-19 were seen in July–September (up to 41% in ED) across all settings. RSV laboratory testing among RSV encounters was low during pre–COVID-19 (IP, 51%; ED, 51%; OP, 41%; UC, 84%) and COVID-19 outside of UC (IP, 33%; ED, 47%; OP, 47%; UC, 87%). Full-term, otherwise healthy infants comprised most RSV encounters (pre–COVID-19, up to 57% in OP; COVID-19, up to 82% in TM). Conclusions: With the interruption of historical RSV epidemiologic trends and the emergence of interseasonal disease during COVID-19, continued monitoring of RSV is warranted across all settings as the changing RSV epidemiology could affect the distribution of health care resources and public health policy.

15 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LBLauren C Bylsma
Lauren C Bylsma
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
JFJon P Fryzek
Jon P Fryzek
CNChristopher B Nelson
Christopher B Nelson
Background: A systematic literature review was conducted to summarize the mortality (overall and by disease severity factors) of US infants and children aged <5 years with respiratory syncytial virus (RSV) or all-cause bronchiolitis (ACB). Methods: Comprehensive, systematic literature searches were conducted; articles were screened using prespecified eligibility criteria. A standard risk of bias tool was used to evaluate studies. Mortality was extracted as the rate per 100 000 or the case fatality ratio (CFR; proportion of deaths among RSV/ACB cases). Results: Among 42 included studies, 36 evaluated inpatient deaths; 10 used nationally representative populations updated through 2013, and only 2 included late-preterm/full-term otherwise healthy infants and children. The RSV/ACB definition varied across studies (multiple International Classification of Diseases [ICD] codes; laboratory confirmation); no study reported systematic testing for RSV. No studies reported RSV mortality rates, while 3 studies provided ACB mortality rates (0.57–9.4 per 100 000). CFRs ranged from 0% to 1.7% for RSV (n = 15) and from 0% to 0.17% for ACB (n = 6); higher CFRs were reported among premature, intensive care unit-admitted, and publicly insured infants and children. Conclusions: RSV mortality reported among US infants and children is variable. Current, nationally representative estimates are needed for otherwise healthy, late-preterm to full-term infants and children.

15 August 2022 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MSMina Suh
Mina Suh
NMNaimisha Movva
Naimisha Movva
LBLauren C Bylsma
Lauren C Bylsma
JFJon P Fryzek
Jon P Fryzek
CNChristopher B Nelson
Christopher B Nelson
Background: The burden and health care utilization (HCU) of respiratory syncytial virus (RSV) in US infants aged <1 year across health care settings are not well characterized. Methods: We systematically reviewed studies of RSV and bronchiolitis published 2000–2021 (data years, 1979–2020). Outcomes included RSV hospitalization (RSVH)/bronchiolitis hospitalization rates, emergency department (ED)/outpatient (OP) visit rates, and intensive care unit (ICU) admissions or mechanical ventilation (MV) use among RSV-/bronchiolitis-hospitalized infants. Study quality was determined using standard tools. Results: We identified 141 good-/fair-quality studies. Five national studies reported annual average RSVH rates (range, 11.6 per 1000 per year among infants aged 6–11 months in 2006 to 50.1 per 1000 per year among infants aged 0–2 months in 1997). Two national studies provided RSVH rates by primary diagnosis for the entire study period (range, 22.0–22.7 per 1000 in 1997–1999 and 1997–2000, respectively). No national ED/OP data were available. Among 11 nonnational studies, RSVH rates varied due to differences in time, populations (eg, prematurity), and locations. One national study reported that RSVH infants with high-risk comorbidities had 5-times more MV use compared to non–high-risk infants in 1997-2012. Conclusions: Substantial data variability was observed. Nationally representative studies are needed to elucidate RSV burden and HCU.